•  Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study
  • Single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion
  • No dose-limiting toxicities, serious adverse events, ICANS, or deaths were reported; infusion-related reactions and CRS were Grade 1–2, and none required glucocorticoids for CRS management
  • Additional translational data showed rapid vector clearance, polyclonal vector integration, and no evidence of non-specific transduction
  • Proof-of-concept progress demonstrates leadership in next-generation cell therapies, with results presented in a late-breaking session at EHA 2026